(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
01 July 2021 (01.07.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/133752 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61K 31/496* (2006.01)
A61K 31/519 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2020/066510

(22) International Filing Date:
22 December 2020 (22.12.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
201911053558 23 December 2019 (23.12.2019) IN

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; Route 206 and Province line Road, Princeton, New Jersey 08543 (US).

(72) Inventors: **VELAPARTHI, Upender**; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). **DARNE, Chetan Padmakar**; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). **OLSON, Richard E.**; c/o Bristol-Myers Squibb Company, 100 Binney Street, Cambridge, Massachusetts 02142 (US). **JALAGAM, Prasada Rao**; c/o Syngene International Limited, Biocon Special Economic Zone, Biocon Park, Plot Nos.2&3, Bommasandra Industrial Area IV phase, Jigani Link Road, Bommasandra, Karnataka, Bangalore 560 099 (IN). **WARRIER, Jayakumar Sankara**; c/o Syngene International Limited, Biocon Special Economic Zone, Biocon Park, Plot Nos.2&3, Bommasandra Industrial Area IV phase, Jigani Link Road, Bommasandra, Karnataka, Bangalore 560 099 (IN).

(74) Agent: **GREENBLATT, Gary D.** et al.; Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS T CELL ACTIVATORS

(57) Abstract: Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is CR_6 or N; Y is CR_3 or N; R_1, R_2, R_3, R_4, R_5, R_6, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.



(I)

WO 2021/133752 A1